277 related articles for article (PubMed ID: 21325596)
1. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions.
Quentin S; Cuccuini W; Ceccaldi R; Nibourel O; Pondarre C; Pagès MP; Vasquez N; Dubois d'Enghien C; Larghero J; Peffault de Latour R; Rocha V; Dalle JH; Schneider P; Michallet M; Michel G; Baruchel A; Sigaux F; Gluckman E; Leblanc T; Stoppa-Lyonnet D; Preudhomme C; Socié G; Soulier J
Blood; 2011 Apr; 117(15):e161-70. PubMed ID: 21325596
[TBL] [Abstract][Full Text] [Related]
2. Numerical chromosomal changes and risk of development of myelodysplastic syndrome--acute myeloid leukemia in patients with Fanconi anemia.
Mehta PA; Harris RE; Davies SM; Kim MO; Mueller R; Lampkin B; Mo J; Myers K; Smolarek TA
Cancer Genet Cytogenet; 2010 Dec; 203(2):180-6. PubMed ID: 21156231
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
4. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
Migas A; Savva N; Mishkova O; Aleinikova OV
Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
[TBL] [Abstract][Full Text] [Related]
5. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
Harada H; Harada Y
Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
[TBL] [Abstract][Full Text] [Related]
6. Molecular Cytogenetic Approach to Characterize Novel and Cryptic Chromosome Abnormalities in Childhood Myeloid Malignances of Fanconi Anemia.
Borges ML; Capela de Matos RR; Amaral BD; Soares-Ventura EM; Leite EP; Silva MO; Cornélio MT; Silva ML; Liehr T; Marques-Salles TD
J Pediatr Hematol Oncol; 2017 Mar; 39(2):e85-e91. PubMed ID: 28212262
[TBL] [Abstract][Full Text] [Related]
7. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
8. Fanconi Anemia patient with AML1 gene amplification and monosomy 7 in pre-transplant myelodysplasia (MDS) relapsing 7 years after successful allo-SCT.
Ayas M; Walter C
Bone Marrow Transplant; 2008 Oct; 42(8):555-7. PubMed ID: 18622412
[No Abstract] [Full Text] [Related]
9. IS THE AMPLIFICATION OF c-MYC, MLL AND RUNX1 GENES IN AML AND MDS PATIENTS WITH TRISOMY 8, 11 AND 21 A FACTOR FOR A CLONAL EVOLUTION IN THEIR KARYOTYPE?
Angelova S; Spassov B; Nikolova V; Christov I; Tzvetkov N; Simeonova M
Tsitol Genet; 2015; 49(3):25-32. PubMed ID: 26214902
[TBL] [Abstract][Full Text] [Related]
10. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
Babushok DV; Bessler M
Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
[TBL] [Abstract][Full Text] [Related]
11. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation.
Wang K; Zhou F; Cai X; Chao H; Zhang R; Chen S
Hematology; 2020 Dec; 25(1):211-218. PubMed ID: 32476595
[No Abstract] [Full Text] [Related]
12. Chromosome abnormalities in bone marrow of Fanconi anemia patients.
Berger R; Le Coniat M; Schaison G
Cancer Genet Cytogenet; 1993 Jan; 65(1):47-50. PubMed ID: 8431915
[TBL] [Abstract][Full Text] [Related]
13. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM
PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
15. Fanconi anemia.
Soulier J
Hematology Am Soc Hematol Educ Program; 2011; 2011():492-7. PubMed ID: 22160080
[TBL] [Abstract][Full Text] [Related]
16. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
Harada H; Harada Y; Kimura A
Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
[TBL] [Abstract][Full Text] [Related]
17. Gains, losses and complex karyotypes in myeloid disorders: a light at the end of the tunnel.
Alvarez S; Cigudosa JC
Hematol Oncol; 2005 Mar; 23(1):18-25. PubMed ID: 16142824
[TBL] [Abstract][Full Text] [Related]
18. Clonality studies and N-ras and p53 mutation analysis of hematopoietic cells in Fanconi anemia.
Venkatraj VS; Gaidano G; Auerbach AD
Leukemia; 1994 Aug; 8(8):1354-8. PubMed ID: 8057673
[TBL] [Abstract][Full Text] [Related]
19. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML.
Dicker F; Haferlach C; Sundermann J; Wendland N; Weiss T; Kern W; Haferlach T; Schnittger S
Leukemia; 2010 Aug; 24(8):1528-32. PubMed ID: 20520634
[No Abstract] [Full Text] [Related]
20. Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.
Ceccaldi R; Briot D; Larghero J; Vasquez N; Dubois d'Enghien C; Chamousset D; Noguera ME; Waisfisz Q; Hermine O; Pondarre C; Leblanc T; Gluckman E; Joenje H; Stoppa-Lyonnet D; Socié G; Soulier J
J Clin Invest; 2011 Jan; 121(1):184-94. PubMed ID: 21183791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
